KP 496

Drug Profile

KP 496

Alternative Names: KP-496; KP-496DPI; KP-496NS; S-36496

Latest Information Update: 02 Jun 2011

Price : $50

At a glance

  • Originator Kaken Pharmaceutical
  • Class Antiasthmatics; Benzoic acids
  • Mechanism of Action Leukotriene D4 receptor antagonists; Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma

Most Recent Events

  • 02 Oct 2009 Kaken completes recruitment in a phase II exploratory trial in perennial Allergic rhinitis in Japan
  • 03 Aug 2007 Preclinical trials in Allergic rhinitis in Japan (Intranasal)
  • 03 Aug 2007 Discontinued - Phase-II for Asthma in Japan (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top